-
Mashup Score: 0Advanced Prostate Cancer Treatment Benefits From Updated Guidelines and Adaptive Sequencing Strategies - 1 year(s) ago
Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JELMYTO Virtual Booth - 1 year(s) ago
JELMYTO by Urogen
Source: experience.jelmyto.comCategories: General Medicine News, Latest HeadlinesTweet-
Did you learn a lot about @JELMYTO at #LUGPA2022? What was your biggest inspiration? Visit the virtual booth to share the reason behind why you treat: https://t.co/2JiLsDR9tW #Sponsored #Urology https://t.co/9ZNey5dX3R
-
-
Mashup Score: 1
“There’s 3000 patient trials that are either done or going to be done within the next year or 2 in the BCG-naïve setting, and all of them have systemic therapy,” says Joshua J. Meeks, MD, PhD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Meeks recaps LUGPA panel on optimizing advanced bladder cancer clinic https://t.co/s9Q4vF3AQG #urology #urologist #LUGPA2022 #bladdercancer
-
-
Mashup Score: 0
“People are starting to retire, and there isn’t that much production of urologists every year; there’s about 270 that come out for the whole country,” says Richard Harris, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Harris discusses staffing and regulatory challenges faced by urologists https://t.co/GkcD4OaiGV #urology #urologist #LUGPA2022
-
-
Mashup Score: 0JELMYTO Virtual Booth - 1 year(s) ago
JELMYTO by Urogen
Source: experience.jelmyto.comCategories: General Medicine News, Latest HeadlinesTweet-
Didn't get to witness the innovative technology of @JELMYTO at #LUGPA2022? Visit the virtual booth for a tangible look inside the innovative technology — and walk through the unique administration process: https://t.co/yiNhHRj0lV #Sponsored #Urology https://t.co/cKsTQsnX32
-
-
Mashup Score: 0
“We want to make sure that independent urology continues to thrive by recruiting new people to independent urology. That’s what we’re going to try and do,” said Evan R. Goldfischer, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
LUGPA President Dr. Goldfischer discusses the challenges facing independent urology https://t.co/k8a1BKNljO #LUGPA2022 #urology #urologist
-
-
Mashup Score: 1Expert discusses unmet needs in urologic care for LGBTQ patients - 1 year(s) ago
“Specifically for our transgender and gender-diverse patients, there are still insurance issues and access issues in general,” said Diana K. Bowen, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Expert discusses unmet needs in urologic care for LGBTQ patients https://t.co/5zlGzEolPz #LUGPA2022 #urology #urologist #healthequity @dkbowen_md @NM_Urology
-
-
Mashup Score: 0New LUGPA president discusses this year's meeting and 2023 goals - 1 year(s) ago
“We have more younger members here at the annual meeting than we’ve ever had before. We want to make that a priority,” says Evan R. Goldfischer, MD, MBA, FACS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
New LUGPA president Dr. Evan R. Goldfischer discusses this year's meeting and 2023 goals https://t.co/vcogAFS781 #LUGPA2022 #urology #urologist @EvanGoldfischer
-
-
Mashup Score: 0JELMYTO Virtual Booth - 1 year(s) ago
JELMYTO by Urogen
Source: experience.jelmyto.comCategories: General Medicine News, Latest HeadlinesTweet-
Currently treating with @JELMYTO in one particular way? This #LUGPA2022 is the time to consider additional paths. Visit the booth to join the discussion on treatment approaches. Learn more here: https://t.co/YgJXJ6imIX #Urology #Sponsored https://t.co/aDOuMkSsZ3
-
-
Mashup Score: 0Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing - 1 year(s) ago
All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing @EAntonarakis @UMNCancer @UrologyUS #LUGPA2022 #LUGPA22 #pcsm https://t.co/x1lklWcQfP
-
Advanced Prostate Cancer Treatment Benefits From Updated Guidelines and Adaptive Sequencing Strategies @HafronJason @OUWB @UrologyUS #pcsm #LUGPA2022 #LUGPA22 https://t.co/0TX1CYeggM